Kornimate/medical-research-clean huggingface dataset:
influencing factors in uveitis

Conditions: Uveitis

Summary: environmental factors possibly influencing uveitis are evaluated.

smoking, nutrition, bmi, education

Eligibility criteria:
inclusion criteria: * patients with uveitis exclusion criteria: * children under 18 years

Keywords: influencing factors (smoking, nutrition, education)
predictors of acute and persistent postoperative pain in lung cancer surgery

Conditions: Lung Cancer

Summary: the aim of this observational study is to investigate if preoperative quantitative sensory testing, anxiety and depression symptoms, and biological markers are associated with the risk of developing acute and chronic postoperative pain after video-assisted thoracoscopic surgery (vats).

this observational study examine acute and chronic postoperative pain in patients undergoing vats. in the study preoperative biomarkers, quantitative sensory testing and questionnaires are used to create prediction models for acute and chronic postoperative pain. the study will serve as background information on the risk factors and predictive factors as well as an exploration of the impact of surgical stress from vats on circulation microrna and inflammatory mediators.

Eligibility criteria:
inclusion criteria: * adults independent of sex with an age of ≥ 18 years * patients scheduled for vats as a part of either examination or radical treatment of lung cancer exclusion criteria: * patients who are unable to understand oral and written information. * patients with known chronic pain in the thorax which have been persisting for at least six months before the day of surgery. * pregnant and nursing women. * patients receiving a planned preoperative epidural blockade during their stay. * patients converted to open surgery.
prevention and treatment of pyrrolitinib-associated diarrhea

Conditions: Breast Cancer

Summary: in this study, patients taking pyrrolitinib alone or combined with pyrrolitinib were recruited (170 cases of secondary prevention and 300 cases of non-secondary prevention). non-secondary prevention: explore the recovery time of oral loperamide 4mg t.i.d. for pyrrolitinib induced diarrhea of 1-2 degrees. secondary prevention: to explore the incidence of grade 3 and above diarrhea during c1d1-c1d22 in patients with oral loperamide 4 mg, t.i.d. (d1-7) →4 mg, b.i.d. (d8-21).

the study can only be formally carried out with the written approval of the ethics committee. investigators regularly submit annual research reports to the ethics committee. investigators will inform the ethics committee in writing when the study is discontinued and / or completed. all patients were required to sign informed consent before entering the group. all updated versions of informed consent and written information will be provided to the subjects during the participant's participation. in the experimental design stage, the statistical principle was used to make reasonable and effective arrangements for the relevant factors. employ statistical experts to calculate the sample size and data statistics, and participate in the design process. data collection and follow-up were conducted by specially assigned personnel, professional doctors were assigned to conduct data review regularly, and special data management personnel were provided. they will ensure the authenticity, reliability and security of data throughout the process.

Eligibility criteria:
inclusion criteria: 1. one of the following two situations: a) plan to take pyrrolitinib for ≥21 days; b) third-degree diarrhea or second-degree diarrhea with complications after taking pyrrolitinib at present, plan to take pyrrolitinib for ≥21 days; 2. age ≥18 years; 3. ecog ps 0-2; 4. life expectancy ≥6 months; 5. participate in this study voluntarily, sign informed consent, have good compliance and are willing to cooperate with the follow-up. exclusion criteria: 1. may be allergic to pyrrolitinib or excipients; 2. there are many factors affecting the absorption of oral drugs, such as inability to swallow, nausea and vomiting; 3. patients with biliary obstruction; 4. participate in other diarrhea-related clinical trials; 5. pregnant and lactating women, fertile women who tested positive in the baseline pregnancy test, or women of childbearing age who were unwilling to use effective contraception during the whole trial period; 6. concomitant diseases (including but not limited to severe hypertension beyond the control of drugs, severe diabetes, etc.) that, according to the judgment of the researcher, seriously endanger the safety of the patient or affect the completion of the study; the investigator concluded that the patient was not eligible for any of the other conditions in the study.

Keywords: diarrhea non-secondary prevention secondary prevention pyrrolitinib
open label trial of acamprosate in bipolar alcoholics

Conditions: Alcohol Dependence; Bipolar Disorder

Summary: the purpose of this study is to determine whether acamprosate (campral) is safe and effective in treating alcohol dependence in individuals with bipolar disorder. all subjects in the study must be currently stabilized on mood-stabilizing medication. half of the subjects will receive acamprosate in addition to their mood-stabilizing medication; control subjects will be maintained on their mood-stabilizing medication alone. measures of alcohol use as well as mood stability will be obtained weekly throughout the active phase of the study.


Eligibility criteria:
inclusion criteria: * adults ages 18-65 * meet dsm-iv criteria for current (past 90 days) alcohol dependence * meet dsm-iv criteria for bipolar i or bipolar ii disorder * currently on a mood stabilizing medication regimen, including the use of lithium, valproic acid, lamotrigine, and/or antipsychotic agent fda approved to treat bipolar disorder without any dosage adjustments in the past month * must be able to remain free from alcohol for at least 3 days prior to medication initiation * subjects must be able to adequately provide informed consent and function at an intellectual level sufficient to allow the accurate completion of all assessment instruments * subjects must consent to random assignment and be willing to commit to medication treatment and follow-up assessments exclusion criteria: * individuals with a primary psychiatric disorder other than bipolar disorder * individuals with an uncontrolled neurologic condition that could confound the results of the study * individuals with an uncontrolled medical condition that may adversely affect the conduct of this trial or jeopardize the subject's safety * participants with creatine clearance less than or equal to half of normal value as indicated by chem. 7 results conducted at screening visit. * concomitant use of other psychotropic medications not allowed per the protocol * women of childbearing potential who are pregnant, lactating or refuse to use adequate forms of birth control * current suicidal or homicidal risk * baseline scores of \> 35 on the montgomery asberg depression rating scale and/or \> 25 on the young mania rating scale

Keywords: acamprosate addiction alcoholism alcohol dependence bipolar disorder depression impulsivity mania substance abuse
the study of jian pi yi shen hua tan granules in cognitive impairment after acute cerebral infarction

Conditions: Cognitive Impairment

Summary: the purpose of this study is to determine whether the chinese medicine jian pi yi shen hua tan granules is effective in the treatment of cognitive impairment after acute cerebral infarction .

the present study is designed to observe the symptoms,syndrome characteristics and neuropsychological changes of patients with cognitive dysfunction after acute cerebral infarction, as well as study the patterns of syndrome evolution and neuropsychological characteristics, in order to provide evidences for the early-stage identification, diagnosis, intervention and treatment based on syndrome differentiation. to assess the effectiveness of applying early-stage prevention on patients with cognitive impairment after acute cerebral infarction through the use of traditional chinese medicine--jian pi yi shen hua tan granules, explore the pathogenesis and therapeutic efficacy mechanism, evaluate the effectiveness of early-stage prevention and provide alternative solutions for preventing or delaying dementia.

Eligibility criteria:
inclusion criteria: * patients conform to the diagnostic criteria of acute ischemic stroke online certificate status protocol classification of cerebral infarction : partial anterior circulation infarct, posterior circulation infarct or lacunar infarction - stroke onset within 14 days * neuropsychological assessments: montreal cognitive assessment scale scores less than 26 points or scores less than 27 points，mmse scores range from 19 points to 26 points * age from forty to eighty, gender not limited * informed and signed the informed consent exclusion criteria: * transient ischemic attack * online certificate status protocol classification of cerebral infarction is a total anterior circulation infarction * stroke patients with the causes of cerebral hemorrhage, subarachnoid hemorrhage, brain tumors, brain injury, or blood diseases and so on. * stroke with an onset of more than 14 days * cerebral embolism caused by atrial fibrillation resulted from rheumatic heart disease, coronary heart disease and other heart diseases. * patients who cannot cooperate with the check due to serious visual, hearing dysfunction, apraxia, aphasia. * patients with other neurological diseases which can affect cognitive function (for example: severe parkinson's disease, normal pressure hydrocephalus, brain tumors, encephalitis) * patients with communication difficulties, or psychiatric disease * depression (hamilton depression scale scores more than or equal to 17 points) diagnosed with alcohol or drug dependence within the past six months * with other diseases which can cause cognitive dysfunction, such as thyroid dysfunction, severe anemia, syphilis, human immunodeficiency virus and so on * with a previous history of stroke and serious sequelae, and cannot cope with neuropsychological examination * with severe primary diseases, and cannot comply with the above scheme

Keywords: traditional chinese medicine granules cognitive impairment acute cerebral infraction prevention
a phase 1 study of wve-007 in adults living with overweight or obesity

Conditions: Obesity and Overweight

Summary: the purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of wve-007 when administered subcutaneously (sc) as single ascending doses in adults who are affected by overweight or obesity.


Eligibility criteria:
inclusion criteria: * male and female participants aged 18 to 60 years * bmi 28 to 35 kg/m2 which has been stable (±5%) for the previous 3 to 6 months (based on participant self-report or medical records) * healthy, in the opinion of the investigator, as determined by prestudy medical history, physical examination, and clinical laboratory assessments exclusion criteria: * history or presence of cv disease, including heart failure (new york heart association \[nyha\] class iii or iv), myocardial infarction, angina, or clinically significant abnormal laboratory assessments * history or presence of thyroid disorders * medical history or diagnosis of causes of liver disease * use of any sirna agent in the prior 12 months * received an investigational agent within 90 days or 5 half-lives, whichever is longer, before the first dose of study drug or are in follow-up of another clinical study
assessment of thrombogenicity in acute coronary syndrome

Conditions: Type 2 Diabetes Mellitus; Acute Coronary Syndrome

Summary: the purpose of this study is to assess platelet dependent thrombogenicity in patients after acute coronary syndrome using an ex vivo arterial injury model.

abnormal platelet activity seen in patients with type2 diabetes mellitus (t2dm) may be an important contributor to their enhanced cardiovascular risk and higher rates of cardiovascular events following acute coronary syndrome, despite dual antiplatelet therapy with aspirin and clopidogrel. we have earlier demonstrated high thrombogenicity in individuals with t2dm and cad in the absence of acute ischaemic events, despite therapeutic doses of aspirin.we hypothesise that patients with t2dm will have increased thrombogenicity after acute coronary syndrome despite optimal secondary prevention medication.measuring ex vivo thrombus area using an arterial injury model simulates plaque rupture and reflects the summative effect of all haemostatic abnormalities. the thrombus area of patients with acs and t2dm will be compared to the controls without t2dm.

Eligibility criteria:
inclusion criteria: * acute coronary syndrome (who criteria) with raised cardiac troponin t * aged 18-80 years * stable acute coronary syndrome * on aspirin and clopidogrel * willing to participate in the study exclusion criteria: * smoking (current smokers or smokers who quit in the last 6 months preceding recruitment) * malignancy (any suspected or proven) * haematological disorders (bleeding disorders) * pre-menopausal women * use of corticosteroids/other antithrombotic agents (warfarin) * chronic liver disease * unable to consent

Keywords: type 2 diabetes mellitus acute coronary syndrome platelet dependent thrombogenicity
reducing opioid use for chronic pain patients following surgery

Conditions: Chronic Pain; Opioid Use; Postoperative Pain; Opioid Dependence

Summary: patients with chronic pain are often prescribed long-term opioid therapy, despite the serious risks and growing concerns related to opioid use. the toronto general hospital has created the world's first multidisciplinary perioperative transitional pain service program (tpsp) aimed at reducing the incidence and severity of chronic post-surgical pain. the tpsp incorporates a variety of mechanisms and interventions to help patients manage pain and to wean off opioids. the approach consists of: pain education, acceptance and commitment therapy (act), and an e-mobile self- management tool to help patients manage chronic pain more effectively. with the tpsp team, the investigators hope to continually assist patients to achieve a balance between the benefits and potential harms of opioid use to promote long-term health and well-being.

the proposed research program encompasses several study designs to evaluate the effectiveness and potential implementation of the tpsp across ontario. the investigators will use three approaches to create a comprehensive evidence-base that can be used to guide future policy and programs related to the management of surgical patients with complex pain and chronic opioid use. in the first phase, a multicenter randomized controlled trial will be conducted in 6 hospital sites to evaluate the effectiveness and potential implementation of tpsp across ontario. the aim is to recruit a total of 210 patients who are currently taking opioids and also undergoing a surgical intervention. the randomized controlled trial will determine the effectiveness of the tpsp at weaning patients completely off opioids while still managing pain after one year. secondly, an economic and healthcare utilization analysis of the program via linkage to provincial administrative databases will be carried out to understand the impact the tpsp program has on the healthcare system as a whole. lastly, a qualitative study will be conducted on both the treatment and control groups. the investigators hope to capture further insight to understand patients and providers experiences of the tpsp intervention.

Eligibility criteria:
inclusion criteria: * ≥ 18 years of age * taking 20 -- 200 mg of preoperative oral morphine equivalents daily * any type of surgical procedure, with the exception of those with palliative intent or organ transplantation * able to read and understand english as posed on the questionnaire surveys prior to informed consent * must be taking opioids for at least one month prior to their operation * must have a personal email address for the set-up of the manage my pain (mmp) app or online multimedia tool exclusion criteria: • subjects who are undergoing palliative care or procedures, organ transplantation, or prescribed with methadone/buprenorphine will be excluded from the trial
the adverse event of mitotane therapy in patients with adrenocortical carcinoma

Conditions: Adrenocortical Carcinoma

Summary: this work will evaluate the adverse effects of mitotane treatment in patients treated for acc with mitotane therapy. all of the individuals were treated at ruijin hospital between may 2023 and may 2024.

background: adrenocortical carcinoma (acc) is a rare malignancy of the adrenal cortex. the annual incidence of acc is thought to be between 0.5-2.0 cases per million. adjunctive therapy with mitotane may be offered post- surgically to minimise risk of recurrence. aims: evaluate the adverse effects of mitotane treatment in patients treated for acc with mitotane therapy. all of the individuals were treated at ruijin hospital between may 2023 and may 2024. methods: cortisol, acth, gastrointestinal reactions and cns toxicity will be measured. spss v27 and graphpad prism v9.3.1 will be used for analysis and illustrations. patients will be included, within acc with mitotane. data will be tested for normality, described as mean± sd, compared using paired sample t-test with 5% p-value for significance and 95% confidence interval (ci).

Eligibility criteria:
inclusion criteria: age ≥ 18 years old and ≤ 75 years diagnosis of patients with adrenocortical cancer gender: males and females provide written informed consent satisfactory compliance exclusion criteria: patients with renal insufficiency (cr\>2 times the upper limit of normal). patients with a history of liver cirrhosis. patients who are currently using corticosteroids. patients with cardiac insufficiency (nyha cardiac function classification grade 3 and above or ef\<50%). patients with stroke and acute myocardial infarction in the past 6 months. patients during pregnancy and lactation

Keywords: mitotane adverse effect
pilonidal sinus disease

Conditions: Pilonidal Sinus

Summary: the aim of this study is to compare the outcomes of karydakis technique versus sinus tract ablation procedure using 1470 nm diode laser for the treatment of pilonidal sinus and provide evidence-based guidance to select the most appropriate operative procedure.


Eligibility criteria:
inclusion criteria: * all patients with a clinical diagnosis of symptomatic uncomplicated pilonidal sinus, males or females, any age will be included in our study. exclusion criteria: * patients with pilonidal abscess and any associated acute condition. * patients with hidradenitis suppurativa. * refusal. * unfit for surgery. * recurrence.
family model diabetes self-management education in faith based organizations

Conditions: Type 2 Diabetes

Summary: this study's objective is to conduct a cluster randomized control study that evaluates the effectiveness of f-dsme (family model diabetes self-management education) when delivered in a group setting in marshallese faith based organizations (fbo). the f-dsme has shown to be effective when delivered in patients' homes, and the proposed research will allow us to determine the f-dsme's effectiveness in a fbo setting.


Eligibility criteria:
inclusion criteria: * self-reported marshallese * 18 years of age or older * have t2d (defined as having an hba1c equal to or greater than 6.5) * have at least one family member willing to take part exclusion criteria: * has received dsme in the past five years * has a condition that makes it unlikely that the participant will be able to follow the protocol, such as terminal illness, non-ambulatory, severe mental illness, severely impaired vision or hearing, eating disorder * plans to move out of the geographic region

Keywords: family model marshallese pacific islander diabetes education
asian study of sacituzumab govitecan (immu-132) in hr+/her2- metastatic breast cancer (mbc)

Conditions: Metastatic Breast Cancer

Summary: the goal of this study is to compare the study drug, sacituzumab govitecan-hziy, versus doctors' treatment of choice in participants with hr+/her2- metastatic breast cancer (mbc) who have failed at least 2 prior chemotherapy regimens.

approximately 330 eligible participants will be randomly allocated to one of the following 2 treatment arms in a 1:1 ratio: investigational arm: sacituzumab govitecan-hziy 10 mg/kg via intravenous (iv) injection administered on day 1 and day 8 (21-day cycle). control arm: recommended doses and schedules as per package insert depending on region. eribulin; capecitabine; gemcitabine; vinorelbine participants will be treated until disease progression as judged by local investigator review, development of unacceptable toxicity, or withdrawal of consent.

Eligibility criteria:
key inclusion criteria: * female or male individuals aged ≥18 years at the time of signing the informed consent form * documented evidence of hormone receptor-positive her2-negative (hr+/her2-) mbc confirmed * refractory to or relapsed after at least 2, and no more than 4, prior systemic chemotherapy regimens for mbc * should have been previously treated with at least 1 taxane in any setting, at least 1 prior anticancer hormonal treatment in any setting * eligible for one of the chemotherapy options listed in the tpc arm * documented radiographic disease progression after the most recent therapy * measurable disease by ct or mri in accordance with recist v 1.1, bone-only disease is not measurable and is not permitted. * adequate bone marrow function, hepatic and renal function * females must not be lactating or pregnant at screening or baseline (as documented by a negative beta human chorionic gonadotropin \[ß-hcg\] key exclusion criteria: * previous treatment with topoisomerase 1 inhibitors as a free form or as other formulations * individuals who have known brain metastases. * have an active second malignancy within 3 years prior to providing informed consent * individuals with active hepatitis b virus (hbv), or hepatitis c virus infection (measurable viral rna load with polymerase chain reaction). * active serious infection requiring systemic antibiotic use within 7 days before cycle1 day 1. * other concurrent medical or psychiatric conditions that, in the investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations. * known hypersensitivity or intolerance to either of the study treatments or any of the excipients. note: other protocol defined inclusion/exclusion criteria may apply.

Keywords: sacituzumab govitecan immu-132 unresectable or metastatic breast cancer hormonal receptor hr positive anti-trop2 human epidermal growth factor receptor 2 (her2) negative antibody drug conjugate
fibroscan predicts complications after hepatectomy

Conditions: Liver Neoplasms

Summary: most of the postoperative complications that may occur after hepatectomy are related to the underlying liver background, and the common preoperative tests do not completely predict such complications. transient elastography by fibroscan is used to calculate the stiffness and the steatosis of the liver, and it may be also used to predict postoperative complications after hepatectomy

a prospective cohort study on consecutive patients scheduled for hepatectomy was planned. fibroscan was performed during the preoperative workup. accuracy of the liver stiffness and steatosis measured by fibroscan in predicting the presence of cirrhosis, of steatosis, and the development of postoperative complications was assessed by roc curve, and multivariate analysis.

Eligibility criteria:
inclusion criteria: * patients with primary and secondary tumors scheduled for hepatectomy at our unit * written consent to get the fibroscan during the preoperative workup exclusion criteria: * refute to get the fibroscan * loss of data

Keywords: complications after hepatectomy